- Home » News and EventsPage 22
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Partners with Bridge Therapeutics on Formulation, Development and Production of New Opioid Addiction Treatment
Dec 10, 2019
Catalent today announced that it has completed clinical production of Bridge Therapeutics Inc.’s opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis® orally disintegrating tablet technology.
Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
Dec 3, 2019
Catalent today announced that it has entered into a partnership with Ethicann to formulate a new combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from multiple sclerosis spasticity.
Catalent to Supply BeiGene’s BTK Inhibitor BRUKINSA™ (zanubrutinib)
Nov 21, 2019
Catalent today announced that it had entered into a long-term commercial supply agreement with BeiGene, Ltd., a biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
Catalent Appoints Corporate Development and Science Leaders to Drive Growth and Innovation
Nov 19, 2019
Catalent today announced it has appointed Mike Grippo as Senior Vice President, Strategy and Corporate Development. Alongside his appointment, Julien Meissonnier has been named as Vice President and Chief Scientific Officer, and will report to Mr. Grippo.
Enhanced Cell Line Productivity Technology to be Introduced by Catalent Biologics at PEGS Europe
Nov 12, 2019
Catalent today announced that Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics will present at the upcoming annual PEGS Europe conference, which will be held at the Lisboa Congress Center, Lisbon, Portugal, on Nov. 18 – 22, 2019.
Catalent’s Chair & Chief Executive Officer, John Chiminski, Receives First Ever ‘Lifetime Achievement’ Award at CPhI Worldwide
Nov 6, 2019
Catalent today announced that its Chair and Chief Executive Officer, John Chiminski, has received the inaugural CPhI Pharma Awards ‘Lifetime Achievement Award’ at CPhI Worldwide.
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Nov 5, 2019
Catalent today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.
Catalent Biologics Launches GPEx® Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity
Nov 4, 2019
Catalent, today announced the launch of its next-generation cell line development technology, GPEx® Boost.
Catalent to Discuss Accelerating Development in Biologics and Gene Therapies as well as Oral Outsourcing Market Trends at CPhI Worldwide
Oct 29, 2019
Catalent (stand 121A82) today announced a busy conference program at the forthcoming CPhI Worldwide annual conference, being held at the Messe Frankfurt, Frankfurt, Germany, on Nov. 5 – 7, 2019.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.